Journal
CLINICAL CANCER RESEARCH
Volume 25, Issue 6, Pages 1880-1888Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-18-0320
Keywords
-
Categories
Funding
- Sanofi
- National Cancer Institute (NCI) [NIH T32 CA062948]
- National Center for Advancing Translational Sciences of the NIH [UL1TR002384]
- NCI [T32 CA203702, R21 CA216800]
Ask authors/readers for more resources
Purpose: Biomarkers aiding treatment optimization in metastatic castration-resistant prostate cancer (mCRPC) are scarce. The presence or absence of androgen receptor (AR) splice variants, AR-V7 and AR(v567es), in mCRPC patient circulating tumor cells (CTC) may be associated with taxane treatment outcomes. Experimental Design: A novel digital droplet PCR (ddPCR) assay assessed AR-splice variant expression in CTCs from patients receiving docetaxel or cabazitaxel in TAXYNERGY (NCT01718353). Patient outcomes were examined according to AR-splice variant expression, including prostate-specific antigen (PSA) 50 response and progression-free survival (PFS). Results: Of the 54 evaluable patients, 36 (67%) were AR-V7(+), 42 (78%) were AR(v567es+), 29 (54%) were double positive, and 5 (9%) were double negative. PSA50 response rates at any time were numerically higher for AR-V7(+) versus AR-V7(+) (78% vs. 58%; P = 0.23) and for AR(v567es+) versus AR(v567es+) (92% vs. 57%; P = 0.04) patients. When AR-V mRNA status was correlated with change in nuclear AR from cycle 1 day 1 to day 8 (n = 24), AR-V7(+) patients (n = 16) had a 0.4% decrease versus a 12.9% and 26.7% decrease in AR-V7(+)/AR(v567es+) (n = 3) and AR-V7(+)/AR(v567es+) (n = 5) patients, respectively, suggesting a dominant role for AR-V7 over AR(v567es). Median PFS was 12.02 versus 8.48 months for AR-V7(+) versus AR-V7(+) (HR = 0.38; P = 0.01), and 12.71 versus 7.29 months for AR(v567es+) versus AR(v567es+) (HR = 0.37; P = 0.02). For AR-V7(+), AR-V7(+)/AR(v567es+), and AR-V7(+)/AR(v567es+) patients, median PFS was 8.48, 11.17, and 16.62 months, respectively (P = 0.0013 for trend). Conclusions: Although detection of both CTC-specific AR-V7 and AR(v567es) by ddPCR influenced taxane outcomes, AR-V7 primarily mediated the prognostic impact. The absence of both variants was associated with the best response and PFS with taxane treatment. See related commentary by Dehm et al., p. 1696
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available